Avalyn Pharma has added on $100 million to accelerate novel inhaled versions of approved drugs for lung conditions. The company’s series D fundraise was led by Suvretta Capital Management and SR One ...

Avalyn Pharma has drawn in another fundraising round, this time a $100 million oversubscribed series D to continue developing ...

Which long-acting inhalers are the most effective and safest for people with advanced chronic obstructive pulmonary disease (COPD)?